These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 422697)

  • 21. Effects of prolonged and brief infusions of noradrenaline on arterial pressure and on the plasma concentrations of active renin, angiotensin II, aldosterone and potassium.
    Casals-Stenzel J; Tree M; Brown JJ; Fraser R; Lever AF; Millar JA; Morton JJ; Robertson JI; Reid JL; Hamilton C
    J Hypertens; 1983 Jun; 1(1):27-35. PubMed ID: 6397510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blunted suppression of plasma renin activity in diabetes.
    Gordon MS; Price DA; Hollenberg NK
    J Renin Angiotensin Aldosterone Syst; 2000 Sep; 1(3):252-6. PubMed ID: 11881033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of sodium restriction and prostaglandin inhibition on the renin-angiotensin system in man.
    Speckart P; Zia P; Zipser R; Horton R
    J Clin Endocrinol Metab; 1977 May; 44(5):832-7. PubMed ID: 870512
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Plasma concentrations of atrial natriuretic hormone in acromegaly: relationship to hypertension.
    Soszyński P; Slowińska-Srzednicka J; Zgliczyński S
    Acta Endocrinol (Copenh); 1991 Sep; 125(3):268-72. PubMed ID: 1835235
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the renin-angiotensin system in the regulation of aldosterone biosynthesis and arterial pressure during sodium deficiency.
    McCaa RE
    Circ Res; 1977 May; 40(5 Suppl 1):I157-62. PubMed ID: 870226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Activity of (des-Aspartyl1)-angiotensin II and angiotensin II in man. Differences in blood pressure and adrenocortical response during normal and low sodium intake.
    Carey RM; Vaughan ED; Peach MJ; Ayers CR
    J Clin Invest; 1978 Jan; 61(1):20-31. PubMed ID: 338631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of an angiotensin II analogue upon blood pressure, plasma renin concentration and plasma aldosterone in hypertensive patients.
    Vierhapper H; Waldhäusl W
    Arzneimittelforschung; 1979; 29(8):1175-7. PubMed ID: 583019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma renin activity and angiotensin I and aldosterone concentrations in cats with hypertension associated with chronic renal disease.
    Jensen J; Henik RA; Brownfield M; Armstrong J
    Am J Vet Res; 1997 May; 58(5):535-40. PubMed ID: 9140564
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Prog Biochem Pharmacol; 1976; 12():230-41. PubMed ID: 1019166
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conn's syndrome in a patient with acromegaly.
    Rioperez E; Botella JM; Valdivieso L; Ballesteros D; Diez L; Navas J
    Horm Metab Res; 1981 Mar; 13(3):186-7. PubMed ID: 7016705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acromegaly and hypertension: prevalence and relationship to the renin-angiotensin-aldosterone system.
    Kraatz C; Benker G; Weber F; Lüdecke D; Hirche H; Reinwein D
    Klin Wochenschr; 1990 Jun; 68(12):583-7. PubMed ID: 2198380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for an angiotensinogenic mechanism of the hypertension of Cushing's syndrome.
    Dalakos TG; Elias AN; Anderson GH; Streeten DH; Schroeder ET
    J Clin Endocrinol Metab; 1978 Jan; 46(1):114-8. PubMed ID: 752014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma renin activity and urinary aldosterone in acromegaly.
    Mantero F; Opocher G; Armanini D; Paviotti G; Boscaro M; Muggeo M
    J Endocrinol Invest; 1979; 2(1):13-8. PubMed ID: 489912
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased adrenal sensitivity to angiotensin II in idiopathic hyperaldosteronism.
    Wisgerhof M; Carpenter PC; Brown RD
    J Clin Endocrinol Metab; 1978 Nov; 47(5):938-43. PubMed ID: 400738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of enalapril maleate on blood pressure, renin-angiotensin-aldosterone system, and peripheral sympathetic activity in essential hypertension.
    Cerasola G; Cottone S; D'Ignoto G; Grasso L; Carone MB; Carapelle E; Contorno A
    Clin Ther; 1987; 9(4):390-9. PubMed ID: 3038326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of bromocriptine treatment on the aldosterone response to angiotensin II and adrenocorticotropin in idiopathic hyperaldosteronism.
    Wisgerhof M; Mellinger RC
    J Clin Endocrinol Metab; 1985 Jul; 61(1):192-5. PubMed ID: 2987293
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulatory effect of the renin-angiotensin system on the plasma levels of calcitonin gene-related peptide in normal man.
    Portaluppi F; Vergnani L; Margutti A; Ambrosio MR; Bondanelli M; Trasforini G; Rossi R; Degli Uberti EC
    J Clin Endocrinol Metab; 1993 Sep; 77(3):816-20. PubMed ID: 8370703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Differences of blood plasma renin activity, angiotensin II and aldosterone levels in essential or secondary hypertension].
    Song AL; Zeng ZP; Tong AL; Lu L; Chen S; Li M; Fu CL; Wang YH; Sun ML
    Zhonghua Nei Ke Za Zhi; 2012 Apr; 51(4):294-8. PubMed ID: 22781950
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological activity of des-Asp1-angiotensin I in man.
    Kono T; Ikeda F; Oseko F; Imura H; Endo J
    J Clin Endocrinol Metab; 1980 Jan; 50(1):40-5. PubMed ID: 7350186
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The renin-angiotensin-aldosterone system in the newborn lamb: response to furosemide.
    Siegel SR; Fisher DA
    Pediatr Res; 1977 Jul; 11(7):837-9. PubMed ID: 876706
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.